At least three people worldwide are infected with totally untreatable “superbug” strains of gonorrhoea which they are likely to be spreading to others through sex, the World Health Organization (WHO) said on Friday.
Giving details of studies showing a “very serious situation” with regard to highly drug-resistant forms of the sexually transmitted disease (STD), WHO experts said it was “only a matter of time” before last-resort gonorrhoea antibiotics would be of no use.
“Gonorrhoea is a very smart bug,” said Teodora Wi, a human reproduction specialist at the Geneva-based U.N. health agency.
“Every time you introduce a new type of antibiotic to treat it, this bug develops resistance to it.”
The WHO estimates 78 million people a year get gonorrhoea, an STD that can infect the genitals, rectum and throat.
The infection, which in many cases has no symptoms on its own, can lead to pelvic inflammatory disease, ectopic pregnancy and infertility, as well as increasing the risk of getting HIV.
Wi, who gave details in a telephone briefing of two studies on gonorrhoea published in the journal PLOS Medicine, said one had documented three specific cases – one each in Japan, France and Spain – of patients with strains of gonorrhoea against which no known antibiotic is effective.
“These are cases that can infect others. It can be transmitted,” she told reporters. “And these cases may just be the tip of the iceberg, since systems to diagnose and report untreatable infections are lacking in lower-income countries where gonorrhoea is actually more common.”
Drug resistance
The WHO’s programme for monitoring trends in drug-resistant gonorrhoea found in a study that from 2009 to 2014 there was widespread resistance to the first-line medicine ciprofloxacin, increasing resistance to another antibiotic drugs called azithromycin, and the emergence of resistance to last-resort treatments known as extended-spectrum cephalosporins (ESCs).
In most countries, it said, ESCs are now the only single antibiotics that remain effective for treating gonorrhoea. Yet resistance to them has already been reported in 50 countries.
Manica Balasegaram, director of the Global Antibiotic Research and Development Partnership, said the situation was “grim” and there was a “pressing need” for new medicines.
The pipeline, however, is very thin, with only three potential new gonorrhoea drugs in development and no guarantee any will prove effective in final-stage trials, he said.
“We urgently need to seize the opportunities we have with existing drugs and candidates in the pipeline,” he told reporters. “Any new treatment developed should be accessible to everyone who needs it, while ensuring it is used appropriately, so that drug resistance is slowed as much as possible.”
